Nektar Therapeutics (NKTR) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $74.35 -0.73%
Revenue Growth %: -7.1%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: -7.1%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.53, $0.14 better than the analyst estimate of $0.39. Revenue for the quarter came in at $132.9 million versus the consensus estimate of $123.2 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
- Keurig Dr Pepper (KDP) PT Raised to $39 at Bernstein SocGen Group
- BMO Capital bullish on top pick Royal Caribbean as cruise tailwinds ’favorable’
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
